CIOMS-WGX-GVA2011Meta-analyses have been increasingly used in the scientific evaluation of efficacy and safety in benefit-risk assessments, as well as for pricing  and the reimbursement of biopharmaceutical products. Over the last few years, the outcome of meta-analyses has been both debated and used as  evidence within the regulatory process for human medicinal products, and their interpretation has ometimes contributed to different regulatory actions for the same product.


Working Group X was established, based on suggestions from several parties, and consists of senior scientists from drug regulatory agencies, the biopharmaceutical industry and academia. The objective is to develop a consensus on scientific and methodological criteria that represents good practices when applied to metaanalyses of clinical data within the regulatory process. The aim is that these criteria will then be used by both industry and regulators. During its first meetings the Working Group decided to focus mainly on meta-analyses of safety data and the title of the Working Group was revised to reflect this.

The members of the Working Group have identified that with increasing amounts of data available in digitized form, publications of meta-analyses of clinical data will likely increase. Apart from methodological caveats, the access to relevant unpublished studies and data submitted only to regulatory agencies or remaining in the files of biopharmaceutical companies, availability of sources of data, the possibility to interact with the researchers involved in the original studies and the resources to re-analyze available data will need to be considered. The ambition is to try to develop a recommendation of a harmonized view on these issues.

In addition, the combining of available information from both randomized clinical trials and epidemiological studies to generate an integrated result is controversial. Criteria as to how this should be done, particularly for safety data, needs to be elaborated and general principles should be established.

It is envisioned that the Working Group will have a series of meetings over a period of three years, aiming for a publication in 2014.





New Meetings

1st Working Group on DILI Meeting, Geneva, Switzerland, 27-28 April 2017

11th Working Group on MedDRA IWG Meeting, Geneva, Switzerland, 22-23 March 2017

CIOMS 84th Executive Committee Meeting, Geneva, Switzerland, 28 November 2017


Recent Meetings

83rd CIOMS Executive Committee/General Assembly Meeting, Geneva, Switzerland, 29 November 2016

10th Working Group on MedDRA IWG Meeting, Geneva, Switzerland, 6-7 September 2016

10th Working Group Meeting on Revision of CIOMS International Ethical Guidelines, Utrecht, Netherlands, 1-3 June 2016

8th CIOMS Working Group Meeting on Vaccine Safety, Accra, Ghana, 22-23 March 2016

9th Working Group on MedDRA IWG Meeting, Geneva, Switzerland, 15-16 March 2016

82nd CIOMS Executive Committee Meeting, Geneva, Switzerland, 8 December 2015

ISoP meeting, Prague, Czech Republic, 27-30 October 2015

8th Working Group on MedDRA IWG Meeting, Geneva, Switzerland, 24-25 September 2015

7th CIOMS Working Group meeting on Vaccine Safety, near Philadelphia, PA, USA, 21-22 September 2015

8th Working Group X on Meta-analysis, New Brunswick, NJ, USA, 1-2 July 2015

9th Working Group on Revision of CIOMS International Ethical Guidelines, Paris, France, 14-16 June 2015

th Working Group on MedDRA IWG, Chavannes-de-Bogis, Switzerland, 19-20 May 2015

8th Working Group on Revision of CIOMS International Ethical Guidelines, Vilnius, Lithuania, 22-24 March 2015

6th Vaccine Safety Working Group, Lyon, France, 18-19 March 2015 

ISoP Meeting, Mysore, India, 12-14 January 2015


WHO on Twitter

WHO Q: Is it ethically correct to offer a test for drug resistant TB when the treatment is not available? A: Yes…
WHO RT @UNICEF: Tuberculosis is not a disease of the past! #WorldTBDay #endTB @WHO
WHO Q: Do governments have an ethical obligation to provide tuberculosis care for free? A: Yes
WHO More than a third (4.3 million) of people with #TB go undiagnosed or unreported, some receive no care at all…
WHO RT @WHOJordan: يمثل اليوم العالمي للسل فرصة لإذكاء الوعي بعبء السل في جميع أنحاء العالم والجهود المبذولة في مجال الوقاية منه ورعاية المصابي…



Member Login

Member Login